A case of non-fatal massive bone marrow necrosis (MBMN) is reported in a patient with primary thrombocythaemia five years after diagnosis. No precipitating cause was identified. The patient developed postnecrotic myelofibrosis six months later. As far as is known, this is the first report of MBMN in a case of primary thrombocythaemia. (i Clin Pathol 1994;47:674-676) Massive bone marrow necrosis (MBMN) is a rare and often terminal complication of both haematological and non-haematological malignancies, usually with bone marrow metastases,' but it has also been reported in non-malignant conditions, such as sickle cell disease.2 We report a case of non-fatal MBMN in a patient with primary thrombocythaemia, a complication which has not been reported before. He continued to be in good health for the next five years and required three to four courses of low dose busulphan every year to keep the platelet count below 450 x 109/1. His haemoglobin and white cell counts remained within the normal range and the platelet count varied between 320 and 450 x 109/1. His blood count just before a holiday in Spain was: haemoglobin 142 g/l; white cell count of 7-2 x 109/1; and a platelet count of 391 x 109/1. While on holiday, he felt unwell, with generalised pain, which was most severe in the ribs and back. He lost his appetite, felt feverish, and sweaty. He was given analgesics, with some relief of his symptoms. His condition improved gradually and the symptoms disappeared after about a week.
Massive bone marrow necrosis and postnecrotic myelofibrosis in a patient with primary thrombocythaemia G Majumdar, J K Phillips, T C Pearson Abstract A case of non-fatal massive bone marrow necrosis (MBMN) is reported in a patient with primary thrombocythaemia five years after diagnosis. No precipitating cause was identified. The patient developed postnecrotic myelofibrosis six months later. As far as is known, this is the first report of MBMN in a case of primary thrombocythaemia. Massive bone marrow necrosis (MBMN) is a rare and often terminal complication of both haematological and non-haematological malignancies, usually with bone marrow metastases,' but it has also been reported in non-malignant conditions, such as sickle cell disease. 2 We report a case of non-fatal MBMN in a patient with primary thrombocythaemia, a complication which has not been reported before. 14 December 1993 Case report A 54 years old man presented with pain in both feet which he had had for six months, with discolouration of the toes for three weeks. He had no previous history of vasoocclusive disease. He smoked 20 cigarettes daily and drank very little alcohol. Clinically there was peripheral cyanosis of the toes but not of the fingers. All peripheral pulses were present and his blood pressure was 150/80 mm Hg. There was no pallor, jaundice, or lymphadenopathy. No atrophic changes were noted in the lower extremities. Systemic examination was normal; in particular, hepatosplenomegaly was absent. There was no evidence of any infection.
A full blood count showed a haemoglobin of 149 g/l, a white cell count of 11. ing 122 g/l, white cell count 5- The present case had a longstanding haematological disease which is associated with marrow hyperplasia, though his disease was apparently under good control when MBMN occurred. His platelet count was within the normal range for several months before the development of MBMN. However, thrombotic complications can occur in patients with primary thrombocythaemia without a high platelet count. This episode might have been related to chemotherapy, though low dose busulphan has never been reported as a causative agent for MBMN. Moreover, this patient had not received busulphan for 11 weeks before the development of MBMN. Therefore, chemotherapy was an unlikely cause for this episode. There was no history of alcohol abuse for our patient, even while on holiday, and no other precipitating factor, such as viral infection, could be identified.
The prognosis of MBMN has been reported to be poor, with very few patients surviving for more than a few weeks.' Recently it has been recognised that the prognosis is related to the underlying disease and not to the MBMN itself which is often underdiagnosed.2 The outcome in our patient seems to be good compared with most of the reported cases of MBMN. However, he has probably developed permanent marrow changes as a result of this episode. 
